Prosight Management LP Grows Stock Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Prosight Management LP grew its stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 11.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 620,000 shares of the company's stock after buying an additional 65,897 shares during the quarter. Syndax Pharmaceuticals makes up 2.3% of Prosight Management LP's portfolio, making the stock its 17th biggest holding. Prosight Management LP owned 0.73% of Syndax Pharmaceuticals worth $8,196,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in SNDX. Parkman Healthcare Partners LLC increased its holdings in Syndax Pharmaceuticals by 3.7% in the 4th quarter. Parkman Healthcare Partners LLC now owns 526,973 shares of the company's stock worth $6,967,000 after acquiring an additional 18,690 shares in the last quarter. Man Group plc purchased a new stake in shares of Syndax Pharmaceuticals in the fourth quarter worth $1,607,000. Octagon Capital Advisors LP purchased a new position in shares of Syndax Pharmaceuticals during the 4th quarter valued at $11,951,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Syndax Pharmaceuticals by 3.5% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 53,748 shares of the company's stock valued at $706,000 after acquiring an additional 1,811 shares during the period. Finally, Lazard Asset Management LLC bought a new position in shares of Syndax Pharmaceuticals in the fourth quarter worth about $153,000.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on SNDX. JPMorgan Chase & Co. lifted their target price on Syndax Pharmaceuticals from $39.00 to $41.00 and gave the company an "overweight" rating in a research note on Thursday, March 20th. Scotiabank increased their price objective on shares of Syndax Pharmaceuticals from $16.00 to $17.00 and gave the company a "sector perform" rating in a report on Tuesday, May 6th. StockNews.com raised shares of Syndax Pharmaceuticals to a "sell" rating in a report on Tuesday, May 6th. HC Wainwright restated a "buy" rating and set a $51.00 target price on shares of Syndax Pharmaceuticals in a research report on Tuesday, March 4th. Finally, Guggenheim reiterated a "buy" rating and issued a $32.00 price target on shares of Syndax Pharmaceuticals in a report on Tuesday, May 6th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have given a buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $35.91.

Syndax Pharmaceuticals Stock Up 9.1%

SNDX traded up $0.85 on Tuesday, hitting $10.15. The company had a trading volume of 1,703,196 shares, compared to its average volume of 2,244,851. The business's fifty day simple moving average is $12.02 and its 200 day simple moving average is $13.97. Syndax Pharmaceuticals, Inc. has a 12-month low of $8.58 and a 12-month high of $25.07. The company has a market cap of $873.20 million, a PE ratio of -2.79 and a beta of 0.82.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last announced its earnings results on Monday, May 5th. The company reported ($0.98) EPS for the quarter, topping analysts' consensus estimates of ($1.04) by $0.06. The company had revenue of $20.04 million during the quarter, compared to analysts' expectations of $15.88 million. During the same quarter last year, the firm posted ($0.85) EPS. Syndax Pharmaceuticals's revenue for the quarter was up 1900.0% compared to the same quarter last year. On average, analysts anticipate that Syndax Pharmaceuticals, Inc. will post -3.72 earnings per share for the current fiscal year.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).